2. 2
Highlights | Corporate
The only Brazilās mixed market player that features exposure and expansion capacity
in the segments of Retail, Hospital & Specialties and Distribution;
Strategic partnership with AmerisourceBergen, the worldās largest player in the
pharmaceutical specialties, resulting in the creation of the company Profarma
Specialty;
The Company carried out four acquisitions between 2012-2014, including its entry
into the Retail pharmaceutical segment, and the attainment of a market position as
2nd largest player within this segment in the state of Rio de Janeiro;
Proven capacity to integrate acquisitions, combining all group companies in the SAP
plataform, BI Cognos and Hyperion.
3. Highlights | 3Q15
3
CONSOLIDATED PRO-FORMA
(considering 100% of all companies)
ā¢ Gross revenue climbed by 13.2%;
ā¢ Consolidated EBITDA increased by 9.2%, up R$29.1 million;
ā¢ Operating expenses fell by 0.5 p.p. in operating expenses, from
12.0% to 11.5%.
RETAIL
ā¢ Drogasmilās and Tamoioās sales rose respectively by 15.8% and
7.1%;
ā¢ Drogasmilās same stores sales (SSS) increased by 11.6% and
Tamoioās by 6.3%;
ā¢ Drogasmilās and Tamoioās average monthly sales per mature store
increased by 7.8% and 6.2%, respectively.
SPECIALTIES
ā¢ The divisionās sales climbed by 23.7%;
ā¢ EBITDA shot up by 151.3% from 3Q14, with EBITDA margin of
3.0%;
ā¢ Sales to the private sector skyrocketed by 54.7%.
PHARMACEUTICAL DISTRIBUTION
ā¢ Sales rose by 10.9%;
ā¢ EBITDA rose by 22.8%, with EBITDA margin of 2.4%;
ā¢ Operating expenses dropped by 0.5 p.p., from 7.9% to 7.4%.
6. 987.4
170.6
1,158.0
Specialties
964.1
214.5
1,178.5
1,072.2
238.9
1,311.2
Consolidated Performance
6
Gross Revenues Evolution
(R$ million)
Pharmaceutical Distribution
Sales rose by 10.9% in comparison
with 3Q14;
The divisionās sales climbed by
23.7% year-over-year;
Drogasmilās and Tamoioās sales rose
respectively by 15.8% and 7.1% in
relation to 3Q14;
3Q14 2Q15 3Q15
11.3 %
13.2 %
Retail
Accounting Consolidated Gross Revenues
Pro-forma Consolidated Gross Revenues: 100% of revenues from
Tamoio and Specialties
15. Pharmaceutical Distribution
2.4
3Q14 3Q15
2.2
7.4
3Q14 3Q15
7.9
9.6
3Q14 3Q15
10.2
1,010.4
3Q14 3Q15
911.3
Sales rose by 10.9%;
15
Operating expenses
dropped by 0.5 p.p., from
7.9% to 7.4%.
EBITDA rose by 22.8%, with
EBITDA margin of 2.4%.
Financial Data
(R$ million and % Net Revenues)
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
17. 17
3,0
1,5
8,9
10,3
12,0
12,7
201,4
162,8
Specialties
The divisionās sales climbed
by 23.7%;
EBITDA shot up by 151.3%
from 3Q14, with EBITDA
margin of 3.0%;
Sales to the private sector
skyrocketed by 54.7%.
3Q14 3Q153Q14 3Q153Q14 3Q153Q14 3Q15
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
Financial Data
(R$ million and % Net Revenues)
19. Financial Data
(R$ million and % Net Revenues)
19
EBITDA Margin
(%)
4.3
3Q14 3Q15
7.6
Op. Exp. SG&A
(%)
23.0
3Q14 3Q15
23.4
Gross Margin
(%)
28.0
3Q14 3Q15
31.1
Gross Revenues
(R$ million)
112.4
3Q14 3Q15
105.0
Retail | Tamoio
The Tamoio chainās sales
rose by 7.1% year-over-year;
Operating expenses fell by
0.4 p.p. in relation to 3Q14;
The average ticket increased
by 7.3% vs. 3Q14.
Average monthly sales per
mature store climbed by
6.2%, from R$585.2
thousand in 3Q14 to R$621.7
thousand in 3Q15;
21. Retail | Tamoio
21
0 Opening
0 Close-downs
0 Reformulated
51 Mature
3Q14
vs.
3Q15
Average Ticket
(in reais)
# of Stores
(units)
3Q14 3Q152Q153Q14 2Q15 3Q15
27.98
30.0129.96
7.3%
0.2%
60
61 61
1.7%
0.0%
22. Financial Data
(R$ million and % Net Revenues)
22
EBITDA Margin
(%)
-3.0
3Q14 3Q15
-1.2
Op. Exp. SG&A
(%)
32.6
3Q14 3Q15
30.9
Gross Margin
(%)
30.9
3Q14 3Q15
32.3
Gross Revenues
(R$ million)
78.6
3Q14 3Q15
67.8
Retail | Drogasmil/Farmalife
Total sales up 18.7% when
compared to 3Q14 sales
(excluding the impact of
store under renovation);
Same stores sales (SSS)
increased by 11.6% in
relation to 3Q14.
Average monthly sales per
mature store rose by 7.8%,
from R$419.8 thousand in
3Q14 to R$452.7 thousand
in 3Q15;